Alzheimer Drug Donanemab Gets No-Go From European Regulator
The European Medicines Agency (EMA) has recommended refusal of a marketing authorization for donanemab, which targets the treatment of early...
Arden Pekar
The European Medicines Agency (EMA) has recommended refusal of a marketing authorization for donanemab, which targets the treatment of early...
